Featured Research

from universities, journals, and other organizations

Research Highlights Possibility of Halting Dental Cavities Epidemic

Date:
May 26, 2006
Source:
Forsyth Institute
Summary:
Researchers at The Forsyth Institute have made significant advances in research to develop a vaccine against cavities. The research team of Martin Taubman, DDS, PhD and Daniel J. Smith PhD, has discovered key molecules that can stimulate a human immune response and has successfully conducted immunization trials in animal models. The global epidemic of dental caries (cavities) highlights the growing imperative to develop a vaccine to prevent cavities.

Researchers at The Forsyth Institute have made significant advances in research to develop a vaccine against cavities. The research team of Martin Taubman, DDS, PhD and Daniel J. Smith PhD, has discovered key molecules that can stimulate a human immune response and has successfully conducted immunization trials in animal models. The global epidemic of dental caries (cavities) highlights the growing imperative to develop a vaccine to prevent cavities.

Dental caries is an infectious disease that occurs when microorganisms accumulate on the teeth, especially in the presence of sucrose (sugar), says Taubman, head of the Department of Immunology at Forsyth. “Oral health is a critical component of general health and well-being,” said Dr. Taubman. “Unfortunately, dental caries remains a chronic problem that is not only widespread in the industrialized world, but is also increasing in prevalence in developing nations. We have a real opportunity to address this public health crisis, and to improve quality of life, while preventing long-term health problems.”

A full report of the scientific and public health imperative for a vaccine against dental caries will be published in the July 2006 issue of Nature Reviews Immunology. (Available online at http://www.nature.com/nri/index.html on May 25.)

“Many people are fortunate enough to never experience the devastating effects of severe dental caries,” said Phil Stashenko, Vice President of Research for The Forsyth Institute. “However, even here in the U.S. dental caries is the most common childhood disease.”

Why A Vaccine is Needed

Worldwide, 5 billion people suffer from tooth decay. The World Oral Health Report 2003, published by the WHO, indicates that dental caries is a major health problem in most industrialized countries, affecting 60-90% of school children and most adults. In the United States, dental caries remains the most common childhood disease five times more common than asthma. At the same time, there are considerable disparities in oral health status, with a sharp increase in cavities among the nation’s poorest children. These children suffer from chronic pain that is caused by abscessed teeth, as well as from the psychological stigma of unsightly decayed teeth.

Dental disease also significantly impacts the national health budget. In the United States, more than $70 billion is spent on dental treatment, a figure that is expected to grow by nearly 10% per year. Thus, over 5% of total US health care budget is committed to treating oral disease. The impact is also felt in other ways. Over 20% of reservists in the US Armed Forces were unable be deployed to Iraq in the recent Middle Eastern conflict.

Forsyth's strategy is aimed at stimulating the production of antibodies that inhibit the enzyme that allows bacteria to accumulate on teeth. The researchers believe that the best way to protect against caries over the long term is to vaccinate children at about the age of one, after teeth have begun to emerge, but before mutans streptococci bacteria have begun to colonize the tooth surfaces. At this stage, Taubman explains, children’s immune systems are developed enough to produce antibodies to prevent accumulation of mutans bacteria and the tooth-decaying acid the bacteria manufacture. Once the bacteria already accumulated, antibodies form, but are not effective in halting decay.

The Forsyth researchers are focusing on "mucosal" vaccines that can be sprayed into the nose for several reasons. Primarily these vaccines are better-targeted to stimulate nasal-associated lymphoid tissues, which can result in antibodies in saliva or other mucosal areas and, they are easier to administer to young children.

The Forsyth Institute is the world’s leading independent nonprofit research organization focused on oral, craniofacial and related biomedical science. Established in 1910, Forsyth’s mission is to lead the discovery, communication and application of breakthroughs in oral health and disease prevention that will significantly improve the health and well-being of the nation and the world.


Story Source:

The above story is based on materials provided by Forsyth Institute. Note: Materials may be edited for content and length.


Cite This Page:

Forsyth Institute. "Research Highlights Possibility of Halting Dental Cavities Epidemic." ScienceDaily. ScienceDaily, 26 May 2006. <www.sciencedaily.com/releases/2006/05/060526070008.htm>.
Forsyth Institute. (2006, May 26). Research Highlights Possibility of Halting Dental Cavities Epidemic. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2006/05/060526070008.htm
Forsyth Institute. "Research Highlights Possibility of Halting Dental Cavities Epidemic." ScienceDaily. www.sciencedaily.com/releases/2006/05/060526070008.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins